CompletedPhase 2NCT00136435
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Daniel J. DeAngelo, MD, PhDDana-Farber Cancer Institute
- Intervention
- prednisone(drug)
- Enrollment
- 100 target
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2002 – 2011
Study locations (12)
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University Of Columbia Medical Center, New York, New York, United States
- Manitoba Blood & Marrow Transplant Program CancerCare Manitoba, Winnipeg, Manitoba, Canada
- McMaster University Medical Center, Hamilton, Ontario, Canada
- Queen's University, Kingston, Ontario, Canada
- London Health Sciences Centre, London, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Hospital Maisonneuve-Rosemont, Montreal, Quebec, Canada
- Royal Victoria Hospital, Montreal, Quebec, Canada
- Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
- Queen Elizabeth II, Halifax, Canada
Collaborators
Brigham and Women's Hospital · Massachusetts General Hospital · Queen Elizabeth II Health Sciences Centre
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00136435 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University